Xyloketal B suppresses glioblastoma cell proliferation and migration in vitro through inhibiting TRPM7-regulated PI3K/Akt and MEK/ERK signaling pathways

Marine Drugs

Volumn 13, Issue 4, 2015, Pages 2505-2525

  Chen, Wen Liang ^a   Turlova, Ekaterina ^a   Sun, Christopher L F ^b   Kim, Ji Sun ^a   Huang, Sammen ^a   Zhong, Xiao ^a   Guan, Yong Yuan ^c   Wang, Guan Lei ^c,d   Rutka, James T ^a   Feng, Zhong Ping ^a   Sun, Hong Shuo ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUN YAT SEN UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Glioblastoma; Marine compound; Migration; Proliferation; TRPM7; Xyloketal B

Indexed keywords

ANTINEOPLASTIC AGENT; CARVACROL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ORGANIC COMPOUND; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; PROTEIN KINASE B; TRANSIENT RECEPTOR POTENTIAL CHANNEL M7; UNCLASSIFIED DRUG; XYLOKETAL B; AKT1 PROTEIN, HUMAN; NERVE PROTEIN; PROTEIN SERINE THREONINE KINASE; PYRAN DERIVATIVE; TRANSIENT RECEPTOR POTENTIAL CHANNEL M; TRPM7 PROTEIN, HUMAN; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; U251 CELL LINE; ANTAGONISTS AND INHIBITORS; AQUATIC SPECIES; CELL MOTION; CELL SURVIVAL; CHEMISTRY; CHINA; DOWN REGULATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MEMBRANE POTENTIAL; METABOLISM; NERVE CELL; PACIFIC OCEAN; PATHOLOGY; TUMOR CELL LINE; WETLAND; XYLARIALES;

FUNGI; XYLARIA;

ANTINEOPLASTIC AGENTS; AQUATIC ORGANISMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHINA; DOWN-REGULATION; GLIOBLASTOMA; HUMANS; MAP KINASE SIGNALING SYSTEM; MEMBRANE POTENTIALS; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; NEURONS; PACIFIC OCEAN; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRANS; SIGNAL TRANSDUCTION; TRPM CATION CHANNELS; WETLANDS; XYLARIALES;

EID: 84928485381     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md13042505     Document Type: Article

References (58)

1. Stupp, R.; Hegi, M.E.; Mason, W.P.; van den Bent, M.J.; Taphoorn, M.J.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.; Fisher, B.; Belanger, K.; et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase iii study: 5-Year analysis of the eortc-ncic trial. Lancet Oncol. 2009, 10, 459-466.
2. Soni, D.; King, J.A.; Kaye, A.H.; Hovens, C.M. Genetics of glioblastoma multiforme: Mitogenic signaling and cell cycle pathways converge. J. Clin. Neurosci. 2005, 12, 1-5.
3. Leon, S.P.; Zhu, J.; Black, P.M. Genetic aberrations in human brain tumors. Neurosurgery 1994, 34, 708-722.
4. Fleming, T.P.; Saxena, A.; Clark, W.C.; Robertson, J.T.; Oldfield, E.H.; Aaronson, S.A.; Ali, I.U. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 1992, 52, 4550-4553.
5. Pelloski, C.E.; Lin, E.; Zhang, L.; Yung, W.K.; Colman, H.; Liu, J.L.; Woo, S.Y.; Heimberger, A.B.; Suki, D.; Prados, M.; et al. Prognostic associations of activated mitogen-activated protein kinase and akt pathways in glioblastoma. Clin. Cancer Res. 2006, 12, 3935-3941.
6. Furnari, F.B.; Fenton, T.; Bachoo, R.M.; Mukasa, A.; Stommel, J.M.; Stegh, A.; Hahn, W.C.; Ligon, K.L.; Louis, D.N.; Brennan, C.; et al. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev. 2007, 21, 2683-2710.
7. Sathornsumetee, S.; Rich, J.N. Designer therapies for glioblastoma multiforme. Ann. N. Y. Acad. Sci. 2008, 1142, 108-132.
8. 2+/calmodulin-dependent protein kinase ii (camkii) in human malignant glioma. J. Biol. Chem. 2010, 285, 11188-11196.
9. Huang, L.; Li, B.; Li, W.; Guo, H.; Zou, F. Atp-sensitive potassium channels control glioma cells proliferation by regulating erk activity. Carcinogenesis 2009, 30, 737-744.
10. Leng, T.D.; Li, M.H.; Shen, J.F.; Liu, M.L.; Li, X.B.; Sun, H.W.; Branigan, D.; Zeng, Z.; Si, H.F.; Li, J.; et al. Suppression of trpm7 inhibits proliferation, migration, and invasion of malignant human glioma cells. CNS Neurosci. Ther. 2015, 21, 252-261.
11. Liu, M.; Inoue, K.; Leng, T.; Guo, S.; Xiong, Z.G. Trpm7 channels regulate glioma stem cell through stat3 and notch signaling pathways. Cell. Signal. 2014, 26, 2773-2781.
12. Sun, H.S.; Jackson, M.F.; Martin, L.J.; Jansen, K.; Teves, L.; Cui, H.; Kiyonaka, S.; Mori, Y.; Jones, M.; Forder, J.P.; et al. Suppression of hippocampal trpm7 protein prevents delayed neuronal death in brain ischemia. Nat. Neurosci. 2009, 12, 1300-1307.
13. 2+ homeostasis. Science 2008, 322, 756-760.
14. Lehen'kyi, V.; Shapovalov, G.; Skryma, R.; Prevarskaya, N. Ion channnels and transporters in cancer. 5. Ion channels in control of cancer and cell apoptosis. Am. J. Physiol. Cell Physiol. 2011, 301, C1281-C1289.
15. Wang, J.; Xiao, L.; Luo, C.H.; Zhou, H.; Hu, J.; Tang, Y.X.; Fang, K.N.; Zhang, Y. Overexpression of trpm7 is associated with poor prognosis in human ovarian carcinoma. Asian Pac. J. Cancer Prev. APJCP 2014, 15, 3955-3958.
16. Rybarczyk, P.; Gautier, M.; Hague, F.; Dhennin-Duthille, I.; Chatelain, D.; Kerr-Conte, J.; Pattou, F.; Regimbeau, J.M.; Sevestre, H.; Ouadid-Ahidouch, H.; et al. Transient receptor potential melastatin-related 7 channel is overexpressed in human pancreatic ductal adenocarcinomas and regulates human pancreatic cancer cell migration. Int. J. Cancer 2012, 131, E851-E861.
17. Yee, N.S.; Kazi, A.A.; Yee, R.K. Cellular and developmental biology of trpm7 channel-kinase: Implicated roles in cancer. Cells 2014, 3, 751-777.
18. Lopez-Guerrero, J.A.; Romero, I.; Poveda, A. Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer. Chin. J. Cancer 2015, 34, 41-49.
19. Alicino, I.; Giglio, M.; Manca, F.; Bruno, F.; Puntillo, F. Intrathecal combination of ziconotide and morphine for refractory cancer pain: A rapidly acting and effective choice. Pain 2012, 153, 245-249.
20. Lin, Y.; Wu, X.; Feng, S.; Jiang, G.; Luo, J.; Zhou, S.; Vrijmoed, L.L.; Jones, E.B.; Krohn, K.; Steingrover, K.; et al. Five unique compounds: Xyloketals from mangrove fungus Xylaria sp. From the south China sea coast. J. Org. Chem. 2001, 66, 6252-6256.
21. Chen, W.L.; Qian, Y.; Meng, W.F.; Pang, J.Y.; Lin, Y.C.; Guan, Y.Y.; Chen, S.P.; Liu, J.; Pei, Z.; Wang, G.L.; et al. A novel marine compound xyloketal b protects against oxidized ldl-induced cell injury in vitro. Biochem. Pharmacol. 2009, 78, 941-950.
22. Zhao, J.; Li, L.; Ling, C.; Li, J.; Pang, J.Y.; Lin, Y.C.; Liu, J.; Huang, R.; Wang, G.L.; Pei, Z.; et al. Marine compound xyloketal B protects pc12 cells against ogd-induced cell damage. Brain Res. 2009, 1302, 240-247.
23. Lu, X.L.; Yao, X.L.; Liu, Z.; Zhang, H.; Li, W.; Li, Z.; Wang, G.L.; Pang, J.; Lin, Y.; Xu, Z.; et al. Protective effects of xyloketal B against mpp+-induced neurotoxicity in caenorhabditis elegans and pc12 cells. Brain Res. 2010, 1332, 110-119.
24. Li, Z.X.; Chen, J.W.; Yuan, F.; Huang, Y.Y.; Zhao, L.Y.; Li, J.; Su, H.X.; Liu, J.; Pang, J.Y.; Lin, Y.C.; et al. Xyloketal B exhibits its antioxidant activity through induction of ho-1 in vascular endothelial cells and zebrafish. Mar. Drugs 2013, 11, 504-522.
25. Xiao, A.J.; Chen, W.; Xu, B.; Liu, R.; Turlova, E.; Barszczyk, A.; Sun, C.L.; Liu, L.; Deurloo, M.; Wang, G.L.; et al. Marine compound xyloketal b reduces neonatal hypoxic-ischemic brain injury. Mar. Drugs 2014, 13, 29-47.
26. Franken, N.A.; Rodermond, H.M.; Stap, J.; Haveman, J.; van Bree, C. Clonogenic assay of cells in vitro. Nat. Protoc. 2006, 1, 2315-2319.
27. Liang, C.C.; Park, A.Y.; Guan, J.L. In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2007, 2, 329-333.
28. Yajima, I.; Kumasaka, M.Y.; Thang, N.D.; Goto, Y.; Takeda, K.; Yamanoshita, O.; Iida, M.; Ohgami, N.; Tamura, H.; Kawamoto, Y.; et al. Ras/raf/mek/erk and pi3k/pten/akt signaling in malignant melanoma progression and therapy. Dermatol. Res. Pract. 2012, 2012, 354191, doi:10.1155/2012/354191.
29. Rich, J.N.; Bigner, D.D. Development of novel targeted therapies in the treatment of malignant glioma. Nat. Rev. Drug Discov. 2004, 3, 430-446.
30. Fang, L.; Zhan, S.; Huang, C.; Cheng, X.; Lv, X.; Si, H.; Li, J. Trpm7 channel regulates pdgf-bb-induced proliferation of hepatic stellate cells via pi3k and erk pathways. Toxicol. Appl. Pharmacol. 2013, 272, 713-725.
31. Parnas, M.; Peters, M.; Dadon, D.; Lev, S.; Vertkin, I.; Slutsky, I.; Minke, B. Carvacrol is a novel inhibitor of drosophila trpl and mammalian trpm7 channels. Cell Calcium 2009, 45, 300-309.
32. Pettigrew, J.D.; Wilson, P.D. Synthesis of xyloketal a, b, c, d, and g analogues. J. Org. Chem. 2006, 71, 1620-1625.
33. Su, J.; Chang, C.; Xiang, Q.; Zhou, Z.W.; Luo, R.; Yang, L.; He, Z.X.; Yang, H.; Li, J.; Bei, Y.; et al. Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome p450 3a: A bioinformatic and animal study. Drug Des. Dev. Ther. 2014, 8, 2555-2602.
34. Li, S.; Shen, C.; Guo, W.; Zhang, X.; Liu, S.; Liang, F.; Xu, Z.; Pei, Z.; Song, H.; Qiu, L.; et al. Synthesis and neuroprotective action of xyloketal derivatives in parkinson's disease models. Mar. Drugs 2013, 11, 5159-5189.
35. Xu, Z.; Li, Y.; Xiang, Q.; Pei, Z.; Liu, X.; Lu, B.; Chen, L.; Wang, G.; Pang, J.; Lin, Y.; et al. Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen. J. Med. Chem. 2010, 53, 4642-4653.
36. Cheng, Y.; Zhao, J.; Qiao, W.; Chen, K. Recent advances in diagnosis and treatment of gliomas using chlorotoxin-based bioconjugates. Am. J. Nucl. Med. Mol. Imaging 2014, 4, 385-405.
37. Wong, A.J.; Ruppert, J.M.; Bigner, S.H.; Grzeschik, C.H.; Humphrey, P.A.; Bigner, D.S.; Vogelstein, B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. USA 1992, 89, 2965-2969.
38. Mellinghoff, I.K.; Wang, M.Y.; Vivanco, I.; Haas-Kogan, D.A.; Zhu, S.; Dia, E.Q.; Lu, K.V.; Yoshimoto, K.; Huang, J.H.; Chute, D.J.; et al. Molecular determinants of the response of glioblastomas to egfr kinase inhibitors. N. Engl. J. Med. 2005, 353, 2012-2024.
39. Klingler-Hoffmann, M.; Bukczynska, P.; Tiganis, T. Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells. Int. J. Cancer 2003, 105, 331-339.
40. Wen, P.Y.; Lee, E.Q.; Reardon, D.A.; Ligon, K.L.; Alfred Yung, W.K. Current clinical development of pi3k pathway inhibitors in glioblastoma. Neuro-Oncology 2012, 14, 819-829.
41. McDowell, K.A.; Riggins, G.J.; Gallia, G.L. Targeting the akt pathway in glioblastoma. Curr. Pharm. Des. 2011, 17, 2411-2420.
42. De Luca, A.; Maiello, M.R.; D'Alessio, A.; Pergameno, M.; Normanno, N. The ras/raf/mek/erk and the pi3k/akt signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin. Ther. Targets 2012, 16 (Suppl. 2), S17-S27.
43. Sathornsumetee, S.; Reardon, D.A.; Desjardins, A.; Quinn, J.A.; Vredenburgh, J.J.; Rich, J.N. Molecularly targeted therapy for malignant glioma. Cancer 2007, 110, 13-24.
44. Sunayama, J.; Matsuda, K.; Sato, A.; Tachibana, K.; Suzuki, K.; Narita, Y.; Shibui, S.; Sakurada, K.; Kayama, T.; Tomiyama, A.; et al. Crosstalk between the pi3k/mtor and mek/erk pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 2010, 28, 1930-1939.
45. Hottinger, A.F.; Stupp, R.; Homicsko, K. Standards of care and novel approaches in the management of glioblastoma multiforme. Chin. J. Cancer 2014, 33, 32-39.
46. Wang, J.; Liao, Q.J.; Zhang, Y.; Zhou, H.; Luo, C.H.; Tang, J.; Wang, Y.; Tang, Y.; Zhao, M.; Zhao, X.H.; et al. Trpm7 is required for ovarian cancer cell growth, migration and invasion. Biochem. Biophys. Res. Commun. 2014, 454, 547-553.
47. Yu, M.; Huang, C.; Huang, Y.; Wu, X.; Li, X.; Li, J. Inhibition of trpm7 channels prevents proliferation and differentiation of human lung fibroblasts. Inflamm. Res. 2013, 62, 961-970.
48. Meng, X.; Cai, C.; Wu, J.; Cai, S.; Ye, C.; Chen, H.; Yang, Z.; Zeng, H.; Shen, Q.; Zou, F.; et al. Trpm7 mediates breast cancer cell migration and invasion through the mapk pathway. Cancer Lett. 2013, 333, 96-102.
49. Inoue, K.; Xiong, Z.G. Silencing trpm7 promotes growth/proliferation and nitric oxide production of vascular endothelial cells via the erk pathway. Cardiovasc. Res. 2009, 83, 547-557.
50. Zeng, Z.; Inoue, K.; Sun, H.; Leng, T.; Feng, X.; Zhu, L.; Xiong, Z.G. Trpm7 regulates vascular endothelial cell adhesion and tube formation. Am. J. Physiol. Cell Physiol. 2015, 308, C308-C318.
51. Berridge, M.J.; Bootman, M.D.; Roderick, H.L. Calcium signalling: Dynamics, homeostasis and remodelling. Nat. Rev. Mol. Cell Biol. 2003, 4, 517-529.
52. Yang, Y.R.; Follo, M.Y.; Cocco, L.; Suh, P.G. The physiological roles of primary phospholipase c. Adv. Biol. Regul. 2013, 53, 232-241.
53. Clark, K.; Middelbeek, J.; Lasonder, E.; Dulyaninova, N.G.; Morrice, N.A.; Ryazanov, A.G.; Bresnick, A.R.; Figdor, C.G.; van Leeuwen, F.N. Trpm7 regulates myosin iia filament stability and protein localization by heavy chain phosphorylation. J. Mol. Biol. 2008, 378, 790-803.
54. Deason-Towne, F.; Perraud, A.L.; Schmitz, C. Identification of ser/thr phosphorylation sites in the c2-domain of phospholipase c gamma2 (plcgamma2) using trpm7-kinase. Cell. Signal. 2012, 24, 2070-2075.
55. Langeslag, M.; Clark, K.; Moolenaar, W.H.; van Leeuwen, F.N.; Jalink, K. Activation of trpm7 channels by phospholipase c-coupled receptor agonists. J. Biol. Chem. 2007, 282, 232-239.
56. Goldberg, L.; Kloog, Y. A ras inhibitor tilts the balance between rac and rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res. 2006, 66, 11709-11717.
57. Chen, W.L.; Huang, X.Q.; Zhao, L.Y.; Li, J.; Chen, J.W.; Xiao, Y.; Huang, Y.Y.; Liu, J.; Wang, G.L.; Guan, Y.Y.; et al. Involvement of kv1.5 protein in oxidative vascular endothelial cell injury. PLoS ONE 2012, 7, e49758.
58. Aarts, M.; Iihara, K.; Wei, W.L.; Xiong, Z.G.; Arundine, M.; Cerwinski, W.; MacDonald, J.F.; Tymianski, M. A key role for trpm7 channels in anoxic neuronal death. Cell 2003, 115, 863-877.